If zolbetuximab was not given in first line in metastatic gastric cancer with CLDN 18.2, would you give it with second line ?

There is no correct answer to this question, as, to the best of my knowledge, zolbetuximab has not been combined with any other regimen than a first-line fluoropyrimidine/platinum regimen.

As a single agent, the drug has modest activity (objective response rate of ORR of 9% in patients whose tumor wa...

The short answer is no. Available data in later lines have shown essentially no single-agent activity (Klempner et al., PMID 37490286). Because zolbetuximab is a chimeric (mouse/human) IgG1 naked antibody that relies entirely on immune effector mechanisms (ADCC and CDC) to kill tumor cells, it does ...